GERD Health-Related Quality of Life Scale
Also known as: GERD-HRQL, GERD-HRQoL
The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
GERD-HRQL is indicated for patients with suspected or confirmed GERD requiring baseline symptom quantification and monitoring of treatment response. It is used at initial assessment to document baseline symptom burden and establish expectations for therapy (goal is typically GERD-HRQL <12). After initiating PPI or other antireflux therapy, GERD-HRQL is repeated at 2–4 weeks to assess early response. GERD-HRQL is widely used in GERD clinical trials as a primary efficacy endpoint. It is less useful in acute presentations (severe pain, dysphagia, alarm symptoms) which require upper endoscopy, and is designed for chronic GERD management, not diagnostic evaluation.
Strengths & limitations
- Brief and practical: 9 items administered in 3–5 minutes; feasible for every office visit and phone follow-up.
- Highly responsive to therapy: GERD-HRQL shows dramatic improvement within 2–4 weeks of PPI initiation; sensitive to treatment changes.
- Validated for GERD: Symptoms and impacts assessed are specific to GERD (heartburn, regurgitation), not generic dyspepsia or reflux.
- Predicts PPI efficacy: Baseline GERD-HRQL, particularly high regurgitation scores, predicts response to PPI vs. poor responders who may need antireflux surgery.
- No endoscopic assessment: GERD-HRQL quantifies symptoms but does not assess endoscopic healing of reflux esophagitis; symptom improvement does not guarantee mucosal healing.
- Symptom-based only: Does not capture complications (Barrett's esophagus, peptic stricture, aspiration), which require endoscopy.
- PPI response ceiling: Many patients achieve GERD-HRQL <12 within 2 weeks of PPI, limiting ability to detect further improvement or differentiate responders.
- Weak correlation with acid exposure: GERD-HRQL correlates only weakly (r ~0.3–0.4) with esophageal acid exposure time on pH monitoring; some patients report severe symptoms with minimal acid exposure (functional heartburn).
Frequently asked
What GERD-HRQL score indicates successful PPI therapy?
GERD-HRQL <12 is generally considered successful symptom control on PPI. Scores 12–18 indicate partial response and may warrant PPI dose increase. Scores >25 indicate poor PPI response, warranting investigation for H. pylori, drug interactions, or alternative diagnoses (functional heartburn, achalasia, IBS-like GERD).
How soon after starting PPI should GERD-HRQL be reassessed?
Most patients show symptom improvement within 3–7 days of PPI initiation. Reassess GERD-HRQL at 2–4 weeks to allow full PPI efficacy (acid suppression plateaus by ~1 week, but symptom resolution may take longer). If significant improvement is not apparent by 4 weeks, increase PPI dose, confirm adherence, or investigate alternative diagnoses.
Can GERD-HRQL be used to diagnose H. pylori infection or Barrett's esophagus?
No. GERD-HRQL quantifies symptoms but does not diagnose underlying conditions. High GERD-HRQL or poor PPI response warrants investigation for H. pylori (serology, stool antigen, breath test), but GERD-HRQL does not perform this assessment. Similarly, GERD-HRQL cannot detect Barrett's esophagus; endoscopy is required.
What if a patient has high GERD-HRQL but normal endoscopy?
This suggests functional heartburn (non-erosive reflux disease with normal pH monitoring) or esophageal hypersensitivity. Do not assume the patient has GERD; obtain pH monitoring or impedance testing if diagnosis is unclear. Treatment approach may shift toward acid-suppressing therapy, neuromodulators (tricyclic antidepressants), or psychological interventions rather than escalating PPI.
Is GERD-HRQL affected by depression or anxiety?
Yes. GERD frequently overlaps with anxiety and depression, which can amplify symptom reporting and reduce quality of life. A patient with mild GERD and significant anxiety may report GERD-HRQL >30, while another with similar acid exposure but no anxiety reports GERD-HRQL <15. Assess psychological comorbidity and consider cognitive-behavioral therapy if depression or anxiety is prominent.
Sources
- Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873. link ↗
How to cite this page
ScholarGate. (2026, June 3). GERD Health-Related Quality of Life Scale. ScholarGate. https://scholargate.app/en/gastroenterology/gerd-hrql
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Gastroparesis Cardinal Symptom IndexGastroenterology↔ compare
- Patient Assessment of Constipation Quality of LifeGastroenterology↔ compare
- Rome IV Irritable Bowel Syndrome CriteriaGastroenterology↔ compare
- Short Inflammatory Bowel Disease QuestionnaireGastroenterology↔ compare